Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Urolithiasis
Published in: Urolithiasis 1/2015

01-01-2015 | Invited Review

Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall’s plaques

Author: Xue-Ru Wu

Published in: Urolithiasis | Special Issue 1/2015

Login to get access

Abstract

Genetically engineered mouse models (GEMMs) have been highly instrumental in elucidating gene functions and molecular pathogenesis of human diseases, although their use in studying kidney stone formation or nephrolithiasis remains relatively limited. This review intends to provide an overview of several knockout mouse models that develop interstitial calcinosis in the renal papillae. Included herein are mice deficient for Tamm-Horsfall protein (THP; also named uromodulin), osteopontin (OPN), both THP and OPN, Na+-phosphate cotransporter Type II (Npt2a) and Na+/H+ exchanger regulatory factor (NHERF-1). The baseline information of each protein is summarized, along with key morphological features of the interstitial calcium deposits in mice lacking these proteins. Attempts are made to correlate the papillary interstitial deposits found in GEMMs with Randall’s plaques, the latter considered precursors of idiopathic calcium stones in patients. The pathophysiology that underlies the renal calcinosis in the knockout mice is also discussed wherever information is available. Not all the knockout models are allocated equal space because some are more extensively characterized than others. Despite the inroads already made, the exact physiological underpinning, origin, evolution and fate of the papillary interstitial calcinosis in the GEMMs remain incompletely defined. Greater investigative efforts are warranted to pin down the precise role of the papillary interstitial calcinosis in nephrolithiasis using the existing models. Additionally, more sophisticated, second-generation GEMMs that allow gene inactivation in a time-controlled manner and “compound mice” that bear several genetic alterations are urgently needed, in light of mounting evidence that nephrolithiasis is a multifactorial, multi-stage and polygenic disease.
Literature
1.
Doyle A, McGarry MP, Lee NA, Lee JJ (2012) The construction of transgenic and gene knockout/knockin mouse models of human disease. Transgenic Res 21:327–349PubMedCentralPubMed
2.
Singh M, Murriel CL, Johnson L (2012) Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res 72:2695–2700PubMed
3.
Kohan DE (2008) Progress in gene targeting: using mutant mice to study renal function and disease. Kidney Int 74:427–437PubMed
4.
Bockamp E, Maringer M, Spangenberg C, Fees S, Fraser S, Eshkind L, Oesch F, Zabel B (2002) Of mice and models: improved animal models for biomedical research. Physiol Genomics 11:115–132PubMed
5.
Zhou H, Liu Y, He F, Mo L, Sun TT, Wu XR (2010) Temporally and spatially controllable gene expression and knockout in mouse urothelium. Am J Physiol Renal Physiol 299:F387–F395PubMedCentralPubMed
6.
Jaeger P (1996) Genetic versus environmental factors in renal stone disease. Curr Opin Nephrol Hypertens 5:342–346PubMed
7.
Robertson WG (1986) Pathophysiology of stone formation. Urol Int 41:329–333PubMed
8.
9.
Khan SR, Kok DJ (2004) Modulators of urinary stone formation. Front Biosci 9:1450–1482PubMed
10.
Kumar V, Lieske JC (2006) Protein regulation of intrarenal crystallization. Curr Opin Nephrol Hypertens 15:374–380PubMed
11.
Mandel N (1994) Crystal–membrane interaction in kidney stone disease. J Am Soc Nephrol 5:S37–S45PubMed
12.
Sakhaee K, Maalouf NM, Sinnott B (2012) Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab 97:1847–1860PubMedCentralPubMed
13.
Moe OW (2006) Kidney stones: pathophysiology and medical management. Lancet 367:333–344PubMed
14.
Holmes RP, Ambrosius WT, Assimos DG (2005) Dietary oxalate loads and renal oxalate handling. J Urol 174:943–947 discussion 947PubMed
15.
Bushinsky DA, Frick KK, Nehrke K (2006) Genetic hypercalciuric stone-forming rats. Curr Opin Nephrol Hypertens 15:403–418PubMed
16.
Park S, Pearle MS (2007) Pathophysiology and management of calcium stones. Urol Clin North Am 34:323–334PubMed
17.
Holmes RP, Assimos DG, Goodman HO (1998) Molecular basis of inherited renal lithiasis. Curr Opin Urol 8:315–319PubMed
18.
Lieske JC, Toback FG (2000) Renal cell–urinary crystal interactions. Curr Opin Nephrol Hypertens 9:349–355PubMed
19.
Koul HK, Koul S, Fu S, Santosham V, Seikhon A, Menon M (1999) Oxalate: from crystal formation to crystal retention. J Am Soc Nephrol 10(Suppl 14):S417–S421PubMed
20.
Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M (2003) Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111:607–616PubMedCentralPubMed
21.
Bagga HS, Chi T, Miller J, Stoller ML (2013) New insights into the pathogenesis of renal calculi. Urol Clin North Am 40:1–12PubMedCentralPubMed
22.
23.
Evan AP, Lingeman JE, Coe FL, Shao Y, Parks JH, Bledsoe SB, Phillips CL, Bonsib S, Worcester EM, Sommer AJ, Kim SC, Tinmouth WW, Grynpas M (2005) Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 67:576–591PubMed
24.
Matlaga BR, Coe FL, Evan AP, Lingeman JE (2007) The role of Randall’s plaques in the pathogenesis of calcium stones. J Urol 177:31–38PubMed
25.
Kumar S, Muchmore A (1990) Tamm-Horsfall protein—uromodulin (1950–1990). Kidney Int 37:1395–1401PubMed
26.
Serafini-Cessi F, Malagolini N, Cavallone D (2003) Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 42:658–676PubMed
27.
Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O (2011) The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int 80:338–347PubMed
28.
El-Achkar TM, Wu XR (2012) Uromodulin in kidney injury: an instigator, bystander, or protector? Am J Kidney Dis 59:452–461PubMedCentralPubMed
29.
El-Achkar TM, Wu XR, Rauchman M, McCracken R, Kiefer S, Dagher PC (2008) Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. Am J Physiol Renal Physiol 295:F534–F544PubMed
30.
El-Achkar TM, McCracken R, Rauchman M, Heitmeier MR, Al-Aly Z, Dagher PC, Wu XR (2011) Tamm-Horsfall protein-deficient thick ascending limbs promote injury to neighboring S3 segments in an MIP-2-dependent mechanism. Am J Physiol Renal Physiol 300:F999–F1007PubMed
31.
El-Achkar TM, McCracken R, Liu Y, Heitmeier MR, Bourgeois S, Ryerse J, Wu XR (2013) Tamm-Horsfall protein translocates to the basolateral domain of thick ascending limbs, interstitium, and circulation during recovery from acute kidney injury. Am J Physiol Renal Physiol 304:F1066–F1075PubMedCentralPubMed
32.
Hession C, Decker JM, Sherblom AP, Kumar S, Yue CC, Mattaliano RJ, Tizard R, Kawashima E, Schmeissner U, Heletky S et al (1987) Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines. Science 237:1479–1484PubMed
33.
Muchmore AV, Decker JM (1985) Uromodulin: a unique 85-kilodalton immunosuppressive glycoprotein isolated from urine of pregnant women. Science 229:479–481PubMed
34.
Pennica D, Kohr WJ, Kuang WJ, Glaister D, Aggarwal BB, Chen EY, Goeddel DV (1987) Identification of human uromodulin as the Tamm-Horsfall urinary glycoprotein. Science 236:83–88PubMed
35.
Yang H, Wu C, Zhao S, Guo J (2004) Identification and characterization of D8C, a novel domain present in liver-specific LZP, uromodulin and glycoprotein 2, mutated in familial juvenile hyperuricaemic nephropathy. FEBS Lett 578:236–238PubMed
36.
Ma L, Liu Y, El-Achkar TM, Wu XR (2012) Molecular and cellular effects of Tamm-Horsfall protein mutations and their rescue by chemical chaperones. J Biol Chem 287:1290–1305PubMedCentralPubMed
37.
Nasr SH, Lucia JP, Galgano SJ, Markowitz GS, VD DA (2008) Uromodulin storage disease. Kidney Int 73:971–976PubMed
38.
Scolari F, Caridi G, Rampoldi L, Tardanico R, Izzi C, Pirulli D, Amoroso A, Casari G, Ghiggeri GM (2004) Uromodulin storage diseases: clinical aspects and mechanisms. Am J Kidney Dis 44:987–999PubMed
39.
40.
Serafini-Cessi F, Monti A, Cavallone D (2005) N-glycans carried by Tamm-Horsfall glycoprotein have a crucial role in the defense against urinary tract diseases. Glycoconj J 22:383–394PubMed
41.
Serafini-Cessi F, Dall’Olio F, Malagolini N (1984) High-mannose oligosaccharides from human Tamm-Horsfall glycoprotein. Biosci Rep 4:269–274PubMed
42.
van Rooijen JJ, Voskamp AF, Kamerling JP, Vliegenthart JF (1999) Glycosylation sites and site-specific glycosylation in human Tamm-Horsfall glycoprotein. Glycobiology 9:21–30PubMed
43.
Pak J, Pu Y, Zhang ZT, Hasty DL, Wu XR (2001) Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem 276:9924–9930PubMed
44.
Cavallone D, Malagolini N, Monti A, Wu XR, Serafini-Cessi F (2004) Variation of high mannose chains of Tamm-Horsfall glycoprotein confers differential binding to type 1-fimbriated Escherichia coli. J Biol Chem 279:216–222PubMed
45.
Mo L, Zhu XH, Huang HY, Shapiro E, Hasty DL, Wu XR (2004) Ablation of the Tamm-Horsfall protein gene increases susceptibility of mice to bladder colonization by type 1-fimbriated Escherichia coli. Am J Physiol Renal Physiol 286:F795–F802PubMed
46.
Bates JM, Raffi HM, Prasadan K, Mascarenhas R, Laszik Z, Maeda N, Hultgren SJ, Kumar S (2004) Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int 65:791–797PubMed
47.
Dou W, Thompson-Jaeger S, Laulederkind SJ, Becker JW, Montgomery J, Ruiz-Bustos E, Hasty DL, Ballou LR, Eastman PS, Srichai B, Breyer MD, Raghow R (2005) Defective expression of Tamm-Horsfall protein/uromodulin in COX-2-deficient mice increases their susceptibility to urinary tract infections. Am J Physiol Renal Physiol 289:F49–F60PubMed
48.
Zhou G, Mo WJ, Sebbel P, Min G, Neubert TA, Glockshuber R, Wu XR, Sun TT, Kong XP (2001) Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J Cell Sci 114:4095–4103PubMed
49.
Wu XR, Kong XP, Pellicer A, Kreibich G, Sun TT (2009) Uroplakins in urothelial biology, function, and disease. Kidney Int 75:1153–1165PubMedCentralPubMed
50.
Wu XR, Sun TT, Medina JJ (1996) In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc Natl Acad Sci USA 93:9630–9635PubMedCentralPubMed
51.
Jovine L, Qi H, Williams Z, Litscher E, Wassarman PM (2002) The ZP domain is a conserved module for polymerization of extracellular proteins. Nat Cell Biol 4:457–461PubMed
52.
Weichhart T, Haidinger M, Horl WH, Saemann MD (2008) Current concepts of molecular defence mechanisms operative during urinary tract infection. Eur J Clin Invest 38(Suppl 2):29–38PubMed
53.
Worcester EM (1996) Inhibitors of stone formation. Semin Nephrol 16:474–486PubMed
54.
Chen WC, Lin HS, Chen HY, Shih CH, Li CW (2001) Effects of Tamm-Horsfall protein and albumin on calcium oxalate crystallization and importance of sialic acids. Mol Urol 5:1–5PubMed
55.
Erwin DT, Kok DJ, Alam J, Vaughn J, Coker O, Carriere BT, Lindberg J, Husserl FE, Fuselier H Jr, Cole FE (1994) Calcium oxalate stone agglomeration reflects stone-forming activity: citrate inhibition depends on macromolecules larger than 30 kilodalton. Am J Kidney Dis 24:893–900PubMed
56.
Fellstrom B, Danielson BG, Ljunghall S, Wikstrom B (1986) Crystal inhibition: the effects of polyanions on calcium oxalate crystal growth. Clin Chim Acta 158:229–235PubMed
57.
Grover PK, Moritz RL, Simpson RJ, Ryall RL (1998) Inhibition of growth and aggregation of calcium oxalate crystals in vitro—a comparison of four human proteins. Eur J Biochem 253:637–644PubMed
58.
Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257:F99–F106PubMed
59.
Hess B (1992) Tamm-Horsfall glycoprotein—inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urol Res 20:83–86PubMed
60.
Hess B (1994) Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Miner Electrolyte Metab 20:393–398PubMed
61.
Mo L, Huang HY, Zhu XH, Shapiro E, Hasty DL, Wu XR (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66:1159–1166PubMed
62.
Liu Y, Mo L, Goldfarb DS, Evan AP, Liang F, Khan SR, Lieske JC, Wu XR (2010) Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein. Am J Physiol Renal Physiol 299:F469–F478PubMedCentralPubMed
63.
Liu Y, El-Achkar TM, Wu XR (2012) Tamm-Horsfall protein regulates circulating and renal cytokines by affecting glomerular filtration rate and acting as a urinary cytokine trap. J Biol Chem 287:16365–16378PubMedCentralPubMed
64.
Wolf MT, Wu XR, Huang CL (2013) Uromodulin upregulates TRPV5 by impairing caveolin-mediated endocytosis. Kidney Int 84:130–137PubMedCentralPubMed
65.
Evan AP, Weinman EJ, Wu XR, Lingeman JE, Worcester EM, Coe FL (2010) Comparison of the pathology of interstitial plaque in human ICSF stone patients to NHERF-1 and THP-null mice. Urol Res 38:439–452PubMedCentralPubMed
66.
Mo L, Liaw L, Evan AP, Sommer AJ, Lieske JC, Wu XR (2007) Renal calcinosis and stone formation in mice lacking osteopontin Tamm-Horsfall protein, or both. Am J Physiol Renal Physiol 293:F1935–F1943PubMed
67.
Mollsten A, Torffvit O (2010) Tamm-Horsfall protein gene is associated with distal tubular dysfunction in patients with type 1 diabetes. Scand J Urol Nephrol 44:438–444PubMed
68.
Sejdiu I, Torffvit O (2008) Decreased urinary concentration of Tamm-Horsfall protein is associated with development of renal failure and cardiovascular death within 20 years in type 1 but not in type 2 diabetic patients. Scand J Urol Nephrol 42:168–174PubMed
69.
Chakraborty J, Below AA, Solaiman D (2004) Tamm-Horsfall protein in patients with kidney damage and diabetes. Urol Res 32:79–83PubMed
70.
Khan SR (2012) Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol Res 40:95–112PubMed
71.
Gudbjartsson DF, Holm H, Indridason OS, Thorleifsson G, Edvardsson V, Sulem P, de Vegt F, d’Ancona FC, den Heijer M, Wetzels JF, Franzson L, Rafnar T, Kristjansson K, Bjornsdottir US, Eyjolfsson GI, Kiemeney LA, Kong A, Palsson R, Thorsteinsdottir U, Stefansson K (2010) Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS Genet 6:e1001039PubMedCentralPubMed
72.
Kumar V, Pena de la Vega L, Farell G, Lieske JC (2005) Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. Kidney Int 68:1784–1792PubMed
73.
Glauser A, Hochreiter W, Jaeger P, Hess B (2000) Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 15:1580–1587PubMed
74.
Romero MC, Nocera S, Nesse AB (1997) Decreased Tamm-Horsfall protein in lithiasic patients. Clin Biochem 30:63–67PubMed
75.
Jaggi M, Nakagawa Y, Zipperle L, Hess B (2007) Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function. Urol Res 35:55–62PubMed
76.
Pourmand G, Nasseh H, Sarrafnejad A, Mehrsai A, Hamidi Alamdari D, Nourijelyani K, Shekarpour L (2005) Urinary Tamm-Horsfall protein and citrate: a case–control study of inhibitors and promoters of calcium stone formation. Urol J 2:79–85PubMed
77.
Youhanna S, Weber J, Beaujean V, Glaudemans B, Sobek J, Devuyst O (2013) Determination of uromodulin in human urine: influence of storage and processing. Nephrol Dial Transplant 29:136–145PubMed
78.
Viswanathan P, Rimer JD, Kolbach AM, Ward MD, Kleinman JG, Wesson JA (2011) Calcium oxalate monohydrate aggregation induced by aggregation of desialylated Tamm-Horsfall protein. Urol Res 39:269–282PubMedCentralPubMed
79.
Knorle R, Schnierle P, Koch A, Buchholz NP, Hering F, Seiler H, Ackermann T, Rutishauser G (1994) Tamm-Horsfall glycoprotein: role in inhibition and promotion of renal calcium oxalate stone formation studied with Fourier-transform infrared spectroscopy. Clin Chem 40:1739–1743PubMed
80.
Standal T, Borset M, Sundan A (2004) Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26:179–184PubMed
81.
Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J (2002) Osteopontin—a molecule for all seasons. QJM 95:3–13PubMed
82.
Rittling SR, Denhardt DT (1999) Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 7:103–113PubMed
83.
Giachelli CM, Steitz S (2000) Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 19:615–622PubMed
84.
Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F (2001) Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 60:1645–1657PubMed
85.
Vattikuti R, Towler DA (2004) Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab 286:E686–E696PubMed
86.
Kleinman JG, Wesson JA, Hughes J (2004) Osteopontin and calcium stone formation. Nephron Physiol 98:43–47
87.
De Yoreo JJ, Qiu SR, Hoyer JR (2006) Molecular modulation of calcium oxalate crystallization. Am J Physiol Renal Physiol 291:F1123–F1131PubMed
88.
Kohri K, Yasui T, Okada A, Hirose M, Hamamoto S, Fujii Y, Niimi K, Taguchi K (2012) Biomolecular mechanism of urinary stone formation involving osteopontin. Urol Res 40:623–637PubMed
89.
Atmani F, Glenton PA, Khan SR (1998) Identification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in the urine of healthy and stone forming subjects. Urol Res 26:201–207PubMed
90.
Atmani F, Khan SR (2002) Quantification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in vitro in the urine of healthy controls and stone-forming patients. Urol Int 68:54–59PubMed
91.
McKee MD, Nanci A, Khan SR (1995) Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 10:1913–1929PubMed
92.
Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL (1998) Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 101:1468–1478PubMedCentralPubMed
93.
Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman JG, Hughes J (2003) Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14:139–147PubMed
94.
Chiocchetti A, Orilieri E, Cappellano G, Barizzone N, DA S, DA G, Lorini R, Ravazzolo R, Cadario F, Martinetti M, Calcaterra V, Cerutti F, Bruno G, Larizza D, Dianzani U (2010) The osteopontin gene +1239A/C single nucleotide polymorphism is associated with type 1 diabetes mellitus in the Italian population. Int J Immunopathol Pharmacol 23:263–269PubMed
95.
Zhao F, Chen X, Meng T, Hao B, Zhang Z, Zhang G (2012) Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer 12:477PubMedCentralPubMed
96.
Marciano R, D’Annunzio G, Minuto N, Pasquali L, Santamaria A, Di Duca M, Ravazzolo R, Lorini R (2009) Association of alleles at polymorphic sites in the osteopontin encoding gene in young type 1 diabetic patients. Clin Immunol 131:84–91PubMed
97.
Naito M, Matsui A, Inao M, Nagoshi S, Nagano M, Ito N, Egashira T, Hashimoto M, Mishiro S, Mochida S, Fujiwara K (2005) SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 40:381–388PubMed
98.
Safarinejad MR, Shafiei N, Safarinejad S (2013) Association between polymorphisms in osteopontin gene (SPP1) and first episode calcium oxalate urolithiasis. Urolithiasis 41:303–313PubMed
99.
Chutipongtanate S, Nakagawa Y, Sritippayawan S, Pittayamateekul J, Parichatikanond P, Westley BR, May FE, Malasit P, Thongboonkerd V (2005) Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor. J Clin Invest 115:3613–3622PubMedCentralPubMed
100.
Tenenhouse HS (2005) Regulation of phosphorus homeostasis by the type iia na/phosphate cotransporter. Annu Rev Nutr 25:197–214PubMed
101.
Iwaki T, Sandoval-Cooper MJ, Tenenhouse HS, Castellino FJ (2008) A missense mutation in the sodium phosphate co-transporter Slc34a1 impairs phosphate homeostasis. J Am Soc Nephrol 19:1753–1762PubMedCentralPubMed
102.
Prie D, Huart V, Bakouh N, Planelles G, Dellis O, Gerard B, Hulin P, Benque-Blanchet F, Silve C, Grandchamp B, Friedlander G (2002) Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 347:983–991PubMed
103.
Courbebaisse M, Leroy C, Bakouh N, Salaun C, Beck L, Grandchamp B, Planelles G, Hall RA, Friedlander G, Prie D (2012) A new human NHERF1 mutation decreases renal phosphate transporter NPT2a expression by a PTH-independent mechanism. PLOS One 7:e34764PubMedCentralPubMed
104.
Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS (1998) Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci USA 95:5372–5377PubMedCentralPubMed
105.
Khan SR, Canales BK (2011) Ultrastructural investigation of crystal deposits in Npt2a knockout mice: are they similar to human Randall’s plaques? J Urol 186:1107–1113PubMedCentralPubMed
106.
Khan SR, Glenton PA (2008) Calcium oxalate crystal deposition in kidneys of hypercalciuric mice with disrupted type IIa sodium-phosphate cotransporter. Am J Physiol Renal Physiol 294:F1109–F1115PubMedCentralPubMed
107.
Khundmiri SJ, Ahmad A, Bennett RE, Weinman EJ, Steplock D, Cole J, Baumann PD, Lewis J, Singh S, Clark BJ, Lederer ED (2008) Novel regulatory function for NHERF-1 in Npt2a transcription. Am J Physiol Renal Physiol 294:F840–F849PubMed
108.
Lederer ED, Khundmiri SJ, Weinman EJ (2003) Role of NHERF-1 in regulation of the activity of Na-K ATPase and sodium-phosphate co-transport in epithelial cells. J Am Soc Nephrol 14:1711–1719PubMed
109.
Gisler SM, Pribanic S, Bacic D, Forrer P, Gantenbein A, Sabourin LA, Tsuji A, Zhao ZS, Manser E, Biber J, Murer H (2003) PDZK1: I. a major scaffolder in brush borders of proximal tubular cells. Kidney Int 64:1733–1745PubMed
110.
Shenolikar S, Voltz JW, Minkoff CM, Wade JB, Weinman EJ (2002) Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting. Proc Natl Acad Sci USA 99:11470–11475PubMedCentralPubMed
111.
Weinman EJ, Mohanlal V, Stoycheff N, Wang F, Steplock D, Shenolikar S, Cunningham R (2006) Longitudinal study of urinary excretion of phosphate, calcium, and uric acid in mutant NHERF-1 null mice. Am J Physiol Renal Physiol 290:F838–F843PubMed
112.
Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5:713–725PubMed
113.
Wu XR (2009) Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev 28:281–290PubMedCentralPubMed
114.
He F, Mo L, Zheng XY, Hu C, Lepor H, Lee EY, Sun TT, Wu XR (2009) Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res 69:9413–9421PubMedCentralPubMed
115.
Watts RW (2005) Idiopathic urinary stone disease: possible polygenic aetiological factors. QJM 98:241–246PubMed
116.
Zerwekh JE, Reed-Gitomer BY, Pak CY (2002) Pathogenesis of hypercalciuric nephrolithiasis. Endocrinol Metab Clin North Am 31:869–884PubMed
117.
Goodman HO, Brommage R, Assimos DG, Holmes RP (1997) Genes in idiopathic calcium oxalate stone disease. World J Urol 15:186–194PubMed
Metadata
Title
Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall’s plaques
Author
Xue-Ru Wu
Publication date
01-01-2015
Publisher
Springer Berlin Heidelberg
Published in
Urolithiasis / Issue Special Issue 1/2015
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-014-0699-3

Other articles of this Special Issue 1/2015

Urolithiasis 1/2015 Go to the issue

Invited Review

Unified theory on the pathogenesis of Randall’s plaques and plugs

Review

Mechanisms of human kidney stone formation

Invited Review

Micro-CT imaging of Randall’s plaques

Invited Review

Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate?

Invited Review

Foreword

Erratum

Erratum to: Randall’s plaques, plugs and the clinical workup of the renal stone patient